Stockscreener 앱 받기
2.10
1.87%
-0.04
시간 외 거래:
2.10
전일 마감가:
$2.14
열려 있는:
$2.18
하루 거래량:
5,487
Relative Volume:
0.33
시가총액:
$193.59M
수익:
$47.04M
순이익/손실:
$-63.98M
주가수익비율:
-2.6042
EPS:
-0.8064
순현금흐름:
$-34.39M
1주 성능:
-2.33%
1개월 성능:
+20.00%
6개월 성능:
+10.53%
1년 성능:
-7.04%
1일 변동 폭
$1.973
$2.18
1주일 범위
$1.973
$2.23
52주 변동 폭
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.10 | 197.70M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 개시 | BTIG Research | Buy |
| 2021-09-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 개시 | Goldman | Neutral |
Innate Pharma Adr 주식(IPHA)의 최신 뉴스
Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail
How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat
Innate Pharma Adr (IPHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):